Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Only subjects who give voluntary written informed consent, and who are willing and able to make reasonable efforts to observe all clinical trial requirements are to be enrolled.~* Subjects will be osteopenic but otherwise healthy postmenopausal women, from 60 to 79 years of age (inclusive) at entry.~* Screening BMD of the lumbar vertebrae (L1-L4) must be between -2.5 SD and~  * 1.0 SD of the T-score.~* Subjects should have a Body Mass Index (BMI) \>19 and \< 30 kg/m2.~Exclusion Criteria:~* Spinal X -ray with symptomatic vertebral fracture (more than 20% reduction in expected vertebral height).~* History of bilateral hip replacements.~* Subjects who are not ambulatory.~* History or presence of any malignancy, except non-melanoma skin cancers.~* TVUS double wall thickness \> 4 mm, or any other undiagnosed abnormalities visualized by TVUS.~* Abnormal cervical Pap smear result~* Undiagnosed abnormal (in the investigator's opinion) vaginal bleeding in the past year prior to screening.~* Mammography or physical examination finding that is suspicious of malignancy.~* Uncontrolled hypertension~* Bone disease other than osteoporosis such as Paget's disease, osteomalacia or bone metastases.~* Drinking more than 4 glasses of alcohol containing drinks per day.~* Smoking more than 20 cigarettes a day.~* Current or recent prolonged use of hepatic microsomal enzyme-inducing anticonvulsant medication or other drugs known to interfere with or otherwise alter the pharmacokinetics of steroids.~* Treatment with anabolic steroids, calcitonin or raloxifene within the last 6 months.~* Treatment with alendronate and risedronate more than 6 months. If treatment duration was less than 6 months a wash-out period of 12 months is necessary.~* Treatment with etidronate for 1 year a wash-out period of 6 months is necessary. If treatment period of more than 1 year a wash -out period of 12 months is necessary.~* Treatment with oral estrogen and/or progestin therapy (including contraceptives) or transdermal therapy and local estrogen applications within 6 months prior to screening/baseline BMD measurements (i.e. the wash -out period of 6 months must have been completed before the screening / baseline BMD assessments are made). A 20-week wash-out for injections of MPA-containing contraceptives (e.g. Depo-Provera®) is required.~* Ever use of estrogen and/or progestin containing implants.~* The use of cholesterol-lowering medicine cholestyramine or colestipol.~* Subjects with a change in thyroid medication within the last 6 weeks prior to screening.~* Subjects who have had fluoride treatment for 2 weeks or more (\> 2 mg/day fluorideion) at any time (NaF tablets for caries prevention is allowed).~* Subjects who have undergone systemic glucocorticoid treatment (\> 5 mg prednisone or equivalent/day) for more than one month within the past 6 months (prior to BMD screening assessments).~* Subjects who are receiving or require medication for the treatment of osteoporosis except Calcium / Vit D.~* The use of coumarin products.~* Type I diabetes mellitus.~* Presence or history of thromboembolic disorders.~* Serious decompensated renal or liver disease.~* Abnormal laboratory values~* Any condition or disease that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): tibolone
- 2 (Type: ACTIVE_COMPARATOR): raloxifene

Based on this trial design, predict the completion outcome and termination type (if applicable).